Lotronex Side Effects

Please note - some side effects for Lotronex may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.

Side Effects of Lotronex - for the Consumer

Lotronex

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome when using Lotronex:

Nausea; mild stomach discomfort and pain.

Seek medical attention right away if any of these SEVERE side effects occur when using Lotronex:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); bloating; bloody diarrhea; bloody stools; constipation; mental or mood changes; new or worsening stomach discomfort or pain; rectal bleeding; severe or persistent nausea; unexplained fever; unusually fast pulse; vomiting.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

Top

Lotronex Side Effects - for the Professional

Lotronex

The following adverse reactions are described in more detail in other sections of the label:

• Complications of constipation [see Boxed Warning, Warnings and Precautions (5.1)]
• Ischemic colitis [see Boxed Warning, Warnings and Precautions (5.2)]

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Patients With Irritable Bowel Syndrome: Table 1 summarizes adverse reactions from 22 repeat-dose studies in patients with IBS who were treated with 1 mg of Lotronex twice daily for 8 to 24 weeks. The adverse reactions in Table 1 were reported in 1% or more of patients who received Lotronex and occurred more frequently on Lotronex than on placebo. A statistically significant difference was observed for constipation in patients treated with Lotronex compared to placebo (p<0.0001).

Table 1. Adverse Reactions Reported in ≥1% of Patients With Irritable Bowel Syndrome and More Frequently on Lotronex 1 mg Twice Daily Than Placebo

		Lotronex
Body System	Placebo	1 mg twice daily
Adverse Reaction	(n = 2,363)	(n = 8,328)
Gastrointestinal
Constipation	6%	29%
Abdominal discomfort and pain	4%	7%
Nausea	5%	6%
Gastrointestinal discomfort and pain	3%	5%
Abdominal distention	1%	2%
Regurgitation and reflux	2%	2%
Hemorrhoids	1%	2%

Gastrointestinal: Constipation is a frequent and dose-related side effect of treatment with Lotronex [see Warnings and Precautions (5.1)]. In clinical studies constipation was reported in approximately 29% of patients with IBS treated with Lotronex 1 mg twice daily (n = 9,316). This effect was statistically significant compared to placebo (p<0.0001). Eleven percent (11%) of patients treated with Lotronex 1 mg twice daily withdrew from the studies due to constipation. Although the number of patients with IBS treated with Lotronex 0.5 mg twice daily is relatively small (n = 243), only 11% of those patients reported constipation and 4% withdrew from clinical studies due to constipation. Among the patients treated with Lotronex 1 mg twice daily who reported constipation, 75% reported a single episode and most reports of constipation (70%) occurred during the first month of treatment, with the median time to first report of constipation onset of 8 days. Occurrences of constipation in clinical trials were generally mild to moderate in intensity, transient in nature, and resolved either spontaneously with continued treatment or with an interruption of treatment. However, serious complications of constipation have been reported in clinical studies and in postmarketing experience [see Boxed Warning and Warnings and Precautions (5.1)]. In Studies 1 and 2, 9% of patients treated with Lotronex reported constipation and 4 consecutive days with no bowel movement [see Clinical Studies (14.2)]. Following interruption of treatment, 78% of the affected patients resumed bowel movements within a 2-day period and were able to re-initiate treatment with Lotronex.

Hepatic: A similar incidence in elevation of ALT (>2-fold) was seen in patients receiving Lotronex or placebo (1.0% vs. 1.2%). A single case of hepatitis (elevated ALT, AST, alkaline phosphatase, and bilirubin) without jaundice in a patient receiving Lotronex was reported in a 12-week study. A causal association with Lotronex has not been established.

Long-Term Safety: Patient experience in controlled clinical trials is insufficient to estimate the incidence of ischemic colitis in patients taking Lotronex for longer than 6 months.

Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome: Table 2 summarizes the gastrointestinal adverse reactions from 1 repeat-dose study in female patients with severe diarrhea-predominant IBS who were treated for 12 weeks. The adverse reactions in Table 2 were reported in 3% or more of patients who received Lotronex and occurred more frequently with Lotronex than with placebo. Other events reported in 3% or more of patients who received Lotronex and occurring more frequently with Lotronex than with placebo included upper respiratory tract infection, viral gastroenteritis, muscle spasms, headaches, and fatigue.

Table 2. Gastrointestinal Adverse Reactions Reported in ≥3% of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome and More Frequently on Lotronex Than Placebo.

		Lotronex	Lotronex	Lotronex
Adverse Reaction	Placebo	0.5 mg once daily	1 mg once daily	1 mg twice daily
	(n = 176)	(n = 175)	(n = 172)	(n = 176)
Constipation	5%	9%	16%	19%
Abdominal pain	3%	5%	6%	7%
Diarrhea	2%	3%	2%	2%
Hemorrhoidal      hemorrhage	2%	3%	2%	2%
Flatulence	2%	2%	1%	3%
Hemorrhoids	2%	1%	1%	3%
Abdominal pain      upper	1%	3%	1%	1%

Adverse reactions reported in another study of 701 women with severe diarrhea-predominant IBS were similar to those shown in Table 2. Gastrointestinal adverse reactions reported in 3% or more of patients who received Lotronex and occurring more frequently with Lotronex than with placebo included constipation (14% and 10% of patients taking Lotronex 1 mg twice daily or 0.5 mg as needed, respectively, compared with 2% taking placebo), abdominal pain, nausea, vomiting, and flatulence. Other events reported in 3% or more of patients who received Lotronex and occurring more frequently with Lotronex than with placebo included nasopharyngitis, sinusitis, upper respiratory tract infection, urinary tract infection, viral gastroenteritis, and cough.

Constipation: Constipation was the most frequent adverse reaction among women with severe diarrhea-predominant IBS represented in Table 2. There was a dose response in the groups treated with Lotronex in the number of patients withdrawn due to constipation (2% on placebo, 5% on 0.5 mg once daily, 8% on 1 mg once daily, and 11% on 1 mg twice daily). Among these patients with severe diarrhea-predominant IBS treated with Lotronex who reported constipation most (75%) reported one episode which occurred within the first 15 days of treatment and persisted for 4 to 5 days.

Other Events Observed During Clinical Evaluation of Lotronex: During its assessment in clinical trials, multiple and single doses of Lotronex were administered, resulting in 11,874 subject exposures in 86 completed clinical studies. The conditions, dosages, and duration of exposure to Lotronex varied between trials, and the studies included healthy male and female volunteers as well as male and female patients with IBS and other indications.

In the listing that follows, reported adverse reactions were classified using a standardized coding dictionary. Only those events that an investigator believed were possibly related to Lotronex, occurred in at least 2 patients, and occurred at a greater frequency during treatment with Lotronex than during placebo administration are presented. Serious adverse reactions occurring in at least 1 patient for whom an investigator believed there was reasonable possibility that the event was related to treatment with Lotronex and occurring at a greater frequency in patients treated with Lotronex than placebo-treated patients are also presented.

In the following listing, events are categorized by body system. Within each body system, events are presented in descending order of frequency. The following definitions are used: infrequent adverse reactions are those occurring on one or more occasion in 1/100 to 1/1,000 patients; rare adverse reactions are those occurring on one or more occasion in fewer than 1/1,000 patients.

Although the events reported occurred during treatment with Lotronex, they were not necessarily caused by it.

 

Blood and Lymphatic: Rare: Quantitative red cell or hemoglobin defects, and hemorrhage.

 

Cardiovascular: Infrequent: Tachyarrhythmias. Rare: Arrhythmias, increased blood pressure, and extrasystoles.

 

Drug Interaction, Overdose, and Trauma: Rare: Contusions and hematomas.

 

Ear, Nose, and Throat: Rare: Ear, nose, and throat infections; viral ear, nose, and throat infections; and laryngitis.

 

Endocrine and Metabolic: Rare: Disorders of calcium and phosphate metabolism, hyperglycemia, hypothalamus/pituitary hypofunction, hypoglycemia, and fluid disturbances.

 

Eye: Rare: Light sensitivity of eyes.

 

Gastrointestinal: Infrequent: Hyposalivation, dyspeptic symptoms, gastrointestinal spasms, ischemic colitis [see Warnings and Precautions (5.2)], and gastrointestinal lesions. Rare: Abnormal tenderness, colitis, gastrointestinal signs and symptoms, proctitis, diverticulitis, positive fecal occult blood, hyperacidity, decreased gastrointestinal motility and ileus, gastrointestinal obstructions, oral symptoms, gastrointestinal intussusception, gastritis, gastroduodenitis, gastroenteritis, and ulcerative colitis.

 

Hepatobiliary Tract and Pancreas: Rare: Abnormal bilirubin levels and cholecystitis.

 

Lower Respiratory: Infrequent: Breathing disorders.

 

Musculoskeletal: Rare: Muscle pain; muscle stiffness, tightness and rigidity; and bone and skeletal pain.

 

Neurological: Infrequent: Hypnagogic effects. Rare: Memory effects, tremors, dreams, cognitive function disorders, disturbances of sense of taste, disorders of equilibrium, confusion, sedation, and hypoesthesia.

 

Non-Site Specific: Infrequent: Malaise and fatigue, cramps, pain, temperature regulation disturbances. Rare: Burning sensations, hot and cold sensations, cold sensations, and fungal infections.

 

Psychiatry: Infrequent: Anxiety. Rare: Depressive moods.

 

Reproduction: Rare: Sexual function disorders, female reproductive tract bleeding and hemorrhage, reproductive infections, and fungal reproductive infections.

 

Skin: Infrequent: Sweating and urticaria. Rare: Hair loss and alopecia; acne and folliculitis; disorders of sweat and sebum; allergic skin reaction; eczema; skin infections; dermatitis and dermatosis; and nail disorders.

 

Urology: Infrequent: Urinary frequency. Rare: Bladder inflammation; polyuria and diuresis; and urinary tract hemorrhage.

Postmarketing Experience

In addition to events reported in clinical trials, the following events have been identified during use of Lotronex in clinical practice. Because they were reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to Lotronex.

 

Gastrointestinal: Impaction, perforation, ulceration, small bowel mesenteric ischemia.

 

Neurological: Headache.

 

Skin: Rash.

Top

Side Effects by Body System - for Healthcare Professionals

Gastrointestinal

In IBS clinical trials, the incidence of serious complications of constipation in women was approximately 1 per 1,000 patients, but approximately 10% of patients on alosetron withdrew prematurely because of constipation.

Gastrointestinal side effects have included constipation as the most common side effect. It has been reported in 29% of treated patients versus 6% for placebo. In IBS clinical trials, the cumulative incidence of ischemic colitis in women was 2 per 1,000 patients over 3 months, and 3 per 1,000 patients over 6 months. Other GI side effects have included abdominal discomfort and pain (7 % vs. 4% for placebo), nausea (6% vs. 5% for placebo), GI discomfort and pain (5% vs. 3% for placebo), hemorrhoids (2% to 3%), hemorrhoidal hemorrhage (2% to 3%), diarrhea (2% to 3%), flatulence (1% to 3%), and upper abdominal pain (1% to 3%), abdominal distention (2% vs. 1% for placebo), and regurgitation and reflux (2% vs. 2% for placebo). Postmarketing surveillance side effects have also included ileus, impaction, obstruction, perforation, ulceration, and small bowel mesenteric ischemia.

Nervous system

Nervous system side effects have included infrequent (1 in 100 to 1 in 1,000 patients) reports of hypnagogic effects. Memory effects, tremors, dreams, cognitive function disorders, disturbances of sense of taste, disorders of equilibrium, confusion, sedation, and hypoesthesia have been reported rarely (fewer than 1 in 1,000 patients). Postmarketing reports have included headache.

Cardiovascular

Cardiovascular side effects have included infrequent (1 in 100 to 1 in 1,000 patients) reports of tachyarrhythmias and rare (fewer than 1 in 1,000 patients) reports of arrhythmias, increased blood pressure and extrasystoles.

Psychiatric

Psychiatric side effects have included infrequent (1 in 100 to 1 in 1,000 patients) reports of anxiety and rare (less than 1 in 1,000 patients) reports of depressive disorders.

Hepatic

Hepatic side effects have included reports of ALT elevations greater than 2 fold in 1% of treated patients compared to 1.2% with placebo. Abnormal bilirubin levels and cholecystitis have been reported rarely. A single case of hepatitis has been reported.

Other

Other side effects have included infrequent (1 in 100 to 1 in 1,000 patients) reports of malaise, fatigue, cramps, pain, and temperature regulation disturbances.

Respiratory

Respiratory side effects have included infrequent (1 in 100 to 1 in 1,000 patients) reports of breathing disorders. Viral respiratory infections have been reported rarely (1 in 1,000 patients).

Genitourinary

Genitourinary side effects have included infrequent (1 in 100 to 1 in 1,000 patients) reports of urinary frequency and rare (fewer than 1 in 1,000 patients) reports of bladder inflammation, polyuria, diuresis, and sexual function disorders.

Dermatologic

Dermatologic side effects have included infrequent (1 in 100 to 1 in 1,000 patients) reports of sweating and urticaria, and rare (fewer than 1 in 1,000 patients) reports of hair loss and alopecia; acne and folliculitis; sweat and sebum disorders; allergic skin reactions; eczema; skin infections; dermatitis and dermatosis; and nail disorders. Postmarketing reports have included rash.

Ocular

Ocular side effects have included photophobia (less than 0.1%).

Musculoskeletal

Musculoskeletal side effects have rarely included muscle pain, muscle stiffness, tightness and rigidity, and bone and skeletal pain.

Hematologic

Hematologic side effects have been reported rarely. These have included quantitative red cell or hemoglobin defects, hemorrhage, and lymphatic signs and symptoms.

Top

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.